Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mutagenic approaches to modifying gap junction phenotype.

S N Zucker1, B J Nicholson

  • 1Department of Biological Sciences, SUNY at Buffalo, NY 14260, USA.

Current Drug Targets
|November 27, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Site-directed mutagenesis reveals putative regions of protein interaction within the transmembrane domains of connexins.

Cell communication & adhesion·2008
Same author

Connexin expression and cell coupling fail to reverse the v-src transformed growth characteristics of a Cx43-/- cell line.

Cell communication & adhesion·2005
Same author

Aberrant gating, but a normal expression pattern, underlies the recessive phenotype of the deafness mutant Connexin26M34T.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2004
Same author

Identification of amino acid residues lining the pore of a gap junction channel.

The Journal of cell biology·2002
Same author

Application of SCAM (substituted cysteine accessibility method) to gap junction intercellular channels.

Cell communication & adhesion·2002
Same author

Size selectivity between gap junction channels composed of different connexins.

Cell communication & adhesion·2002
Same journal

Extracellular Vesicles from Mesenchymal Stem Cells Alleviate Spinal Cord Injury via the miR-486-5p/PTEN/PI3K/AKT Pathway.

Current drug targets·2026
Same journal

Improving B-cell Linear Epitope Prediction <i>via</i> Multiple Feature Fusion and an Integrated Machine Learning Algorithm.

Current drug targets·2026
Same journal

Mechanistic Insights into the Inhibition of Plasmodium falciparum DNA Gyrase A by Withanolide Derivatives through Integrated Computational Analysis.

Current drug targets·2026
Same journal

Epitranscriptomics in Breast Cancer: The Unveiled Role of RNA Modifications.

Current drug targets·2026
Same journal

Neuroinflammation in Alzheimer's Disease: New Approaches.

Current drug targets·2026
Same journal

FXYD3: A Key Regulator of Ion Homeostasis and Redox Balance in Cancer Biology.

Current drug targets·2026
See all related articles

Modulating gap junction communication by targeting connexins is crucial for treating diseases. Understanding channel gating mechanisms can lead to new therapies for conditions like cancer and stroke.

Area of Science:

  • Cellular Biology
  • Biochemistry
  • Pharmacology

Background:

  • Gap junctions facilitate intercellular communication vital for normal cell function.
  • Dysfunctional gap junctions are implicated in various diseases, necessitating therapeutic intervention.
  • Connexin 43 (Cx43) is a key gap junction protein whose gating is critical for cellular processes.

Purpose of the Study:

  • To explore the mechanisms of gap junction channel gating.
  • To identify therapeutic strategies for modulating connexin function in disease states.
  • To leverage structure-function insights for developing targeted gap junction modulators.

Main Methods:

  • Analysis of connexin structure-function relationships, focusing on the C-terminal tail of Cx43.
  • Investigation of factors influencing channel gating, including phosphorylation, pH, and growth factors.

Related Experiment Videos

  • Exploration of computational modeling for designing gap junction modulators.

    • Main Results:

    • Specific residues in the Cx43 C-terminal tail are key sites for phosphorylation and binding, directly impacting channel gating.
    • External factors like pH and insulin influence gap junction gating through the C-terminal domain.
    • Understanding pore-lining residues and permeability is essential for developing specific inhibitors.

    Conclusions:

    • Targeting connexin channel gating offers a promising therapeutic avenue for diseases including cancer, arrhythmias, diabetic lens complications, and stroke.
    • Rational drug design based on structural and functional insights can yield site-directed modulators of gap junction communication.
    • Future research holds potential for developing novel treatments by precisely controlling gap junction activity.